CD23.CAR⁺ T cells control tumor growth in a CLL xenograft model. (A-B) 10 × 10⁶ MEC-1 tumor cells were inoculated subcutaneously in the left flank of Rag2^−/−γc^−/− male mice. To test the therapeutic efficacy of CD23.CAR⁺ T cells, mice bearing an established tumor were inoculated IV with 10 × 10⁶ NT or CD23.CAR⁺ T cells derived from different donors for each experiment. Tumor growth was then monitored as tumor diameter per day. Data represent the means ± SD of 3 mice for each panel presented. *P ≤ .05 and **P < .005, respectively, comparing CD23.CAR⁺ and NT T lymphocytes.